80年代土耳其译制电影,80年代外国电影|80年代外国电影有哪些_80年代外国经典电影在线播放地址是多少?

[1]侯毅翰,許中.頭孢他啶阿維巴坦對(duì)抗感染治療患者53例療效的影響因素分析[J].福建醫(yī)藥雜志,2021,43(06):18-21.
 HOU Yihan,XU Zhong.Analysis of the clinical influencing factors of ceftazidime-avibactam for 53 anti-infection patients[J].FUJIAN MEDICAL JOURNAL,2021,43(06):18-21.
點(diǎn)擊復(fù)制

頭孢他啶阿維巴坦對(duì)抗感染治療患者53例療效的影響因素分析()
分享到:

《福建醫(yī)藥雜志》[ISSN:1002-2600/CN:35-1071/R]

卷:
43
期數(shù):
2021年06期
頁(yè)碼:
18-21
欄目:
臨床研究
出版日期:
2021-12-15

文章信息/Info

Title:
Analysis of the clinical influencing factors of ceftazidime-avibactam for 53 anti-infection patients
文章編號(hào):
1002-2600(2021)06-0018-04
作者:
侯毅翰許中1
廈門大學(xué)附屬第一醫(yī)院(廈門 361000)
Author(s):
HOU Yihan XU Zhong
The First Affiliated Hospital of Xiamen University,Xiamen,Fujian 361000,China
關(guān)鍵詞:
頭孢他啶阿維巴坦 抗感染治療 療效 影響因素
Keywords:
ceftazidime-avibactam anti-infection therapy clinical effect influencing factor
分類號(hào):
R453.2
文獻(xiàn)標(biāo)志碼:
B
摘要:
目的 探討頭孢他啶阿維巴坦療效的影響因素。方法 將我院53例使用頭孢他啶阿維巴坦抗感染治療的住院患者根據(jù)其病原微生物的監(jiān)測(cè)結(jié)果分為目標(biāo)性抗感染治療組(目標(biāo)組)和經(jīng)驗(yàn)性抗感染治療組(經(jīng)驗(yàn)組),采用回顧性分析總結(jié)相關(guān)臨床資料,比較兩組間各個(gè)因素的差異,并對(duì)兩組間有差異的因素進(jìn)行l(wèi)ogistic回歸分析。結(jié)果 組內(nèi)比較,兩組患者治療后的體溫、降鈣素原(PCT)、C反應(yīng)蛋白(CRP)、白介素-6(IL-6)都較治療前差異具有統(tǒng)計(jì)學(xué)意義(P<0.05),而腦利鈉肽(BNP)差異無統(tǒng)計(jì)學(xué)意義(P>0.05); 組間比較,治療后兩組患者間的體溫、PCT、CRP差異具有統(tǒng)計(jì)學(xué)意義(P<0.05)。兩組在多發(fā)感染、粒細(xì)胞減少、惡性腫瘤(含血液系統(tǒng)惡性腫瘤)、接受器官或組織移植、建立人工氣道、使用激素方面差異存在統(tǒng)計(jì)學(xué)意義(P<0.05)。logistic回歸分析中,結(jié)果發(fā)現(xiàn),粒細(xì)胞減少和惡性腫瘤(含血液系統(tǒng)惡性腫瘤)可能是頭孢他啶阿維巴坦療效的影響因素。結(jié)論 雖然頭孢他啶阿維巴坦在目標(biāo)性與經(jīng)驗(yàn)性抗感染上均顯示出良好的療效,但在一定程度上前者優(yōu)于后者。粒細(xì)胞減少和惡性腫瘤(含血液系統(tǒng)惡性腫瘤)可能影響頭孢他啶阿維巴坦經(jīng)驗(yàn)性抗感染治療的效果。
Abstract:
Objective To analyze the clinical influencing factors of ceftazidime-avibactam for anti-infection patients. Methods A total of 53 patients in our hospital who were treated with ceftazidime-avibactam were divided into targeted anti-infection group(targeted group)and empirical anti-infection group(empirical group)according to the test of pathogen microbes. The clinical data was summarized by retrospective method.The differences of various factors between the two groups were compared,and the factors with differences between the two groups were analyzed by logistic regression.Results Compared with the data before treating with ceftazidime-avibactam,the temperature,procalcitonin(PCT),C-reactive protein(CRP),interleukin-6(IL-6)were statistically significant after treating with ceftazidime-avibactam in both groups(P<0.05),but brain natriuretic peptide(BNP)was not statistically significant(P>0.05). After treating with ceftazidime-avibactam, the temperature, PCT, and CRP were statistically significant between the two groups(P<0.05). The differences of polyinfection, granulocytopenia, malignant tumor including hematological malignancies, organ or tissue transplantation, intubation of the artificial airway and using glucocorticoid were statistically significant between the two groups(P<0.05). In logistic regression analysis,the results showed that granulocytopenia and malignant tumor including hematological malignancies may be the influencing factors of ceftazidime-avibactam for anti-infection patients. Conclusion Although ceftazidime-avibactam displays excellent efficacy both in targeted and empirical anti-infection treatment,but the former is better than the later to some extent. Granulocytopenia and malignant tumor including hematological malignancies may be the influencing factors of ceftazidime-avibactam for anti-infection patients in the empirical treatment.

參考文獻(xiàn)/References:

[1] Cira M,Echeverria-Palencia C M,Callejas I,et al.Commercially available garden products as important sources of antibiotic resistance genes-a survey[J].Environ Sci Pollut Res Int,2021,28(32):43507-43514.
[2] Wang Y N,Lyu N,Liu F,et al.More diversified antibiotic resistance genes in chickens and workers of the live poultry markets[J].Environ Int,2021,153:106534.
[3] Plaza-Rodríguez C,Alt K,Grobbel M,et al.Wildlife as Sentinels of Antimicrobial Resistance in Germany?[J].Front Vet Sci,2021,7:627821.
[4] Jewell M J,Leyenaar J,Shieh M S,et al.Unnecessary antibiotic prescribing in children hospitalised for asthma exacerbation:a retrospective national cohort study[J].BMJ Qual Saf,2021,30(4):292-299.
[5] 國(guó)家衛(wèi)生健康委合理用藥專家委員會(huì),全國(guó)細(xì)菌耐藥監(jiān)測(cè)網(wǎng).2019年全國(guó)細(xì)菌耐藥監(jiān)測(cè)報(bào)告[J].中國(guó)合理用藥探索,2021,18(3):1-11.
[6] Koeth L M,Matuschek E,Kahlmeter G,et al.Development of EUCAST zone diameter breakpoints and quality control criteria for ceftazidime-avibactam 10-4 ug[J].Eur J Clin Microbiol Infect Dis,2018,37(6):1047-1053.
[7] Clerici D,Oltolini C,Greco R,et al.The place of ceftazi-dime/avibactam and ceftolozane/tazobactam for therapy of haematological patients with febrile neutropenia[J].Int J Antimicrob Agents,2021,57(6):106335.
[8] 閆晨華,徐婷,鄭曉云,等.中國(guó)血液病患者中性粒細(xì)胞缺乏伴發(fā)熱的多中心、前瞻性流行病學(xué)研究[J].中華血液學(xué)雜志,2016,37(3):177-182.
[9] 中華醫(yī)學(xué)會(huì)血液學(xué)分會(huì),中國(guó)醫(yī)師協(xié)會(huì)血液科醫(yī)師分會(huì).中國(guó)中性粒細(xì)胞缺乏伴發(fā)熱患者抗菌藥物臨床應(yīng)用指南(2020年版)[J].中華血液學(xué)雜志,2020,41(12):969-978.
[10] 徐春暉,宿揚(yáng),呂燕霞,等.肛周皮膚拭子細(xì)菌培養(yǎng)對(duì)血液病患者耐碳青霉烯類腸桿菌血流感染的預(yù)警價(jià)值[J].中華血液學(xué)雜志,2018,39(12):1021-1025.
[11] Zheng C C,Tang B L,Zhu X Y,et al.Pre-engraftment bloodstream infections in acute leukemia patients undergoing unrelated cord blood transplantation following intensified myeloablative conditioning without ATG[J].Ann Hematol, 2017,96(1):115-124.
[12] Zaragoza R, Vidal-Cortés P, Aguilar G, et al.Update of the treatment of nosocomial pneumonia in the ICU[J].Crit Care,2020,24(1):383.
[13] Tumbarello M,Trecarichi E M,Corona A,et al.Efficacy of ceftazidime-avibactam salvage therapy in patients with infections caused by Klebsiella pneumoniae Carbapenemase-producing K.pneumoniae[J].Clin Infect Dis,2019,68(3):355-364.
[14] Abdel-Azim H,Sun W L,Wu L T.Strategies to generate functionally normal neutrophils to reduce infection and infection-related mortality in cancer chemotherapy[J].Pharmacol Ther,2019,204:107403.

備注/Memo

備注/Memo:
1 通信作者,Email:[email protected]
更新日期/Last Update: 2021-12-15